Cargando…

P04-32. Differential regulation of secondary antibody responses to Gag and Env proteins

Detalles Bibliográficos
Autores principales:	Nabi, G, Temchura, V, Grossmann, C, Kuate, S, Tenbusch, M, Uberla, K
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2009
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2767963/ http://dx.doi.org/10.1186/1742-4690-6-S3-P60

Ejemplares similares

GagPol-specific CD4(+) T-cells increase the antibody response to Env by intrastructural help
por: Nabi, Ghulam, et al.
Publicado: (2013)

Correction: GagPol-specific CD4(+) T-cells increase the antibody response to Env by intrastructural help
por: Nabi, Ghulam, et al.
Publicado: (2013)

T cell independent secondary antibody responses to the envelope protein of simian immunodeficiency virus
por: Nabi, Ghulam, et al.
Publicado: (2012)

P19-32. HIV-1 vaccine design based on human vaccine trials to improve Gag, Pol, Nef and Env specific immune responses
por: Wild, J, et al.
Publicado: (2009)

Intrastructural Help: Harnessing T Helper Cells Induced by Licensed Vaccines for Improvement of HIV Env Antibody Responses to Virus-Like Particle Vaccines
por: Elsayed, Hassan, et al.
Publicado: (2018)

P04-24. Frequencies of HIV Env-specific B cells and neutralizing antibodies during DNA-prime/protein-boost immunization with three different Env immunogens*
por: Tawde, P, et al.
Publicado: (2009)

Endogenous retrovirus type W GAG and ENV antigenaemia in serum of schizophrenic patients
por: Bernard, Corinne, et al.
Publicado: (2009)

Correction for Elsayed et al., “Intrastructural Help: Harnessing T Helper Cells Induced by Licensed Vaccines for Improvement of HIV Env Antibody Responses to Virus-Like Particle Vaccines”
por: Elsayed, Hassan, et al.
Publicado: (2022)

P04-30. Sorting of infectious and non-infectious viral particles by Env-specific mAb
por: Stieh, DJ, et al.
Publicado: (2009)

N-terminal foamy virus Gag domains and individual residues are critical for capsid assembly and interaction with the unique Env leader protein Elp for Env-dependent budding
por: Liu, Yang, et al.
Publicado: (2013)

Enhancement of immunostimulatory properties of exosomal vaccines by incorporation of fusion-competent G protein of vesicular stomatitis virus
por: Temchura, Vladimir V., et al.
Publicado: (2008)

Maternal intranasal immunization with HTLV-1 Env induces Env specific antibody responses in breast milk
por: Suzuki, Tadaki
Publicado: (2015)

Enhancement of the priming efficacy of DNA vaccines encoding dendritic cell-targeted antigens by synergistic toll-like receptor ligands
por: Grossmann, Claudius, et al.
Publicado: (2009)

Coordinated changes of HIV-1 Gag and Env during assembly and maturation
por: Kräusslich, Hans-Georg
Publicado: (2013)

P04-01. Simultaneous enumeration of HIV-1 gp41 Env-specific IgG and IgM antibody-secreting cells with a multiplex B-cell fluorospot assay
por: Bonsignori, M, et al.
Publicado: (2009)

P04.32. Acupuncture and heart rate variability: a systems level approach to understanding mechanism
por: Anderson, B, et al.
Publicado: (2012)

Epitope mapping of CD8+ T cells on bovine leukemia virus Gag, Env and Tax protein in cattle with different bovine MHC DRB3 alleles
por: Bai, Lanlan, et al.
Publicado: (2015)

P04-04. The specific phospholipid binding and neutralizing activities of the anti-HIV antibody 4E10 are separable
por: Xu, H, et al.
Publicado: (2009)

Neutralizing antibodies elicited in rabbits by patient-derived Env trimer immunization
por: Heyndrickx, L, et al.
Publicado: (2012)

Calcium Phosphate Nanoparticle-Based Vaccines as a Platform for Improvement of HIV-1 Env Antibody Responses by Intrastructural Help
por: Damm, Dominik, et al.
Publicado: (2019)

P20-08. Glycosylation: an important factor in Env diversity
por: Desaire, H, et al.
Publicado: (2009)

P19-06. The first hypervariable loop and HIV-1 neutralizing antibodies elicited by gp140 env immunogens
por: Ching, LK, et al.
Publicado: (2009)

Recognition and penetration of the HIV-1 Env glycan shield by potent broadly neutralizing antibodies
por: Julien, J, et al.
Publicado: (2012)

P04-08. Monoclonal antibodies from patient with acute HIV-1 infection
por: Chen, W, et al.
Publicado: (2009)

P09-07. Balancing reversion of CTL and neutralizing antibody escape mutations within HIV-1 Env upon transmission
por: Peut, V, et al.
Publicado: (2009)

P04-31. Abstract withdrawn
Publicado: (2009)

P04-29. HIV-1 neutralizing antibodies inhibit plasmacytoid dendritic cells infection
por: Lederle, A, et al.
Publicado: (2009)

P04-33. Mechanisms of HIV-1 antibody mediated inhibition in Monomac-1 and MDM
por: Fischetti, L, et al.
Publicado: (2009)

P04-05. Requirements for antibody domain exchange explored through mutation of the germline 2G12 antibody
por: Huber, M, et al.
Publicado: (2009)

CCL28 induces mucosal homing of HIV-1-specific IgA-secreting plasma cells in mice immunized with HIV-1 Virus-like Particles
por: Rainone, V, et al.
Publicado: (2012)

A novel rabbit monoclonal antibody platform to dissect the diverse repertoire of antibody epitopes for HIV-1 Env immunogen design
por: Chen, Y, et al.
Publicado: (2012)

Viral vector delivery of Env trimer immunogens
por: Parks, CL, et al.
Publicado: (2012)

Recombinant Env proteins that bind the quaternary-specific, V1/V2-directed PGT antibodies
por: Gorman, J, et al.
Publicado: (2012)

P04-47. High-titer autologous and heterologous neutralizing antibody activity in acute SIV-infection
por: Schweighardt, B, et al.
Publicado: (2009)

P04-15. Prevalence of broadly neutralizing antibody responses during acute/early HIV infection
por: Mikell, I, et al.
Publicado: (2009)

P04-04 Non-invasive biomarkers with high discriminant ability indicative of musculoskeletal health with ageing
por: Agyapong-Badu, Sandra, et al.
Publicado: (2022)

P14-04. HIV-SELECTEST EIA and rapid test: a novel assay for differential diagnosis of HIV infections in the face of vaccine-generated antibodies
por: Khurana, S, et al.
Publicado: (2009)

P13-03. Neutralizing antibody to HIV-1 Env from hyperimmune bovine colostrum as a mucosal microbicide strategy for preventing virus transmission
por: Kramski, M, et al.
Publicado: (2009)

P17-14. Fitness-informed HIV-1 Gag-p24 vaccine design
por: Rolland, MM, et al.
Publicado: (2009)

P04-26. Immunological tolerance prevents the expression of a broadly reactive neutralizing HIV-1 antibody
por: Verkoczy, L, et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_6c9l1a4pfm46d2prvgi748bt60